Hodgie, one thing to consider mate.....I will suggest that the circa 5%
value from Goetz is purely for the partnership with GSK, I don't think
any valuation would be based on pre-clinical research....
The market certainly wouldn't, the news out in the next week or so
will give us a better indication of where 761 is headed.....
just my thoughts...
Immunotherapy Market value, page-40
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.3¢ |
Change
0.008(2.46%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.5¢ | 30.5¢ | $133.7K | 425.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 123202 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 97102 | 12 |
View Market Depth
| Last trade - 10.30am 25/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
